Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
24
KZIA Quote, Financials, Valuation and Earnings
Last price:
$6.72
Seasonality move
:
15.2%
Day range:
$6.25 - $6.93
52-week range:
$2.86 - $17.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
311.32x
P/B ratio:
2.19x
Volume:
144.8K
Avg. volume:
1.4M
1-year change:
-22.15%
Market cap:
$11.5M
Revenue:
$27.2K
EPS (TTM):
-$6.67
Analysts' Opinion
-
Consensus RatingKazia Therapeutics Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.01, Kazia Therapeutics Ltd. has an estimated upside of 176.4% from its current price of $6.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.97 representing 100% downside risk from its current price of $6.89.
Fair Value
-
According to the consensus of 1 analyst, Kazia Therapeutics Ltd. has 176.4% upside to fair value with a price target of $19.01 per share.
KZIA vs. S&P 500
-
Over the past 5 trading days, Kazia Therapeutics Ltd. has underperformed the S&P 500 by -18.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kazia Therapeutics Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kazia Therapeutics Ltd. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Kazia Therapeutics Ltd. reported revenues of --.
Earnings Growth
-
Kazia Therapeutics Ltd. has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Kazia Therapeutics Ltd. reported earnings per share of --.
Enterprise value:
9.7M
EV / Invested capital:
--
Price / LTM sales:
311.32x
EV / EBIT:
--
EV / Revenue:
0.47x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-1.28x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-106.28%
Net Income Margin (TTM):
--
Return On Equity:
-1083.16%
Return On Invested Capital:
-784.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2006-06-30 | 2007-06-30 | 2008-06-30 | 2007-06-30 | 2008-06-30 | |
| Income Statement | ||||||
| Revenue | $10.1M | $8.4M | -- | $2.8M | $2.7M | |
| Gross Profit | $5.5M | $2.5M | $2.4M | -- | -- | |
| Operating Income | -- | -$26.5M | -- | -$34M | -$34.2M | |
| EBITDA | -- | -$25.8M | -- | -$34M | -$34.2M | |
| Diluted EPS | -$118.40 | -$154.03 | -$178.74 | -$201.49 | -$216.67 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $7.1M | $4.1M | -- | |
| Total Assets | -- | -- | $18.6M | $14.4M | -- | |
| Current Liabilities | -- | -- | $5M | $17.2M | -- | |
| Total Liabilities | -- | -- | $10.6M | $21.1M | -- | |
| Total Equity | -- | -- | $8M | -$6.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.5M | -$12.8M | -$6.5M | -$9M | -$8.3M | |
| Cash From Investing | $1.7M | -- | -$1.2M | -- | $9.4K | |
| Cash From Financing | $2.5M | $22.5M | $4.6M | $17.3M | $12.2K | |
| Free Cash Flow | -$3.5M | -$12.8M | -$6.5M | -- | -- | |
KZIA
Sector
Market Cap
$11.5M
$28.1M
Price % of 52-Week High
39.6%
50%
Dividend Yield
0%
0%
Shareholder Yield
-48.1%
-1.54%
1-Year Price Total Return
-22.15%
-17.67%
Beta (5-Year)
1.739
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.24
200-day SMA
Sell
Level
$7.05
Bollinger Bands (100)
Sell
Level
6.3 - 10.22
Chaikin Money Flow
Sell
Level
-68.1M
20-day SMA
Sell
Level
$10.70
Relative Strength Index (RSI14)
Sell
Level
40.03
ADX Line
Sell
Level
20.86
Williams %R
Buy
Level
-89.5362
50-day SMA
Sell
Level
$8.94
MACD (12, 26)
Sell
Level
-0.72
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
111.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-40.9053)
Sell
CA Score
(Annual)
Level (-10.8714)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (22.8998)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Stock Forecast FAQ
In the current month, KZIA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KZIA average analyst price target in the past 3 months is $19.01.
-
Where Will Kazia Therapeutics Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kazia Therapeutics Ltd. share price will rise to $19.01 per share over the next 12 months.
-
What Do Analysts Say About Kazia Therapeutics Ltd.?
Analysts are divided on their view about Kazia Therapeutics Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kazia Therapeutics Ltd. is a Sell and believe this share price will drop from its current level to $17.97.
-
What Is Kazia Therapeutics Ltd.'s Price Target?
The price target for Kazia Therapeutics Ltd. over the next 1-year time period is forecast to be $19.01 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KZIA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kazia Therapeutics Ltd. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of KZIA?
You can purchase shares of Kazia Therapeutics Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kazia Therapeutics Ltd. shares.
-
What Is The Kazia Therapeutics Ltd. Share Price Today?
Kazia Therapeutics Ltd. was last trading at $6.72 per share. This represents the most recent stock quote for Kazia Therapeutics Ltd.. Yesterday, Kazia Therapeutics Ltd. closed at $6.89 per share.
-
How To Buy Kazia Therapeutics Ltd. Stock Online?
In order to purchase Kazia Therapeutics Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get KZIA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KZIA
Sector
P/E ratio
--
23.88x
PEG ratio
-0.01x
-0.01x
P/B ratio
2.19x
1.81x
Price / LTM sales
311.32x
1.59x
Growth Metrics
KZIA
Sector
Revenue growth
--
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
KZIA
Sector
Profitability FY 2025
-$577.7K
$3.6M
Return on invested capital
-784.09%
-31.77%
Return on assets
-106.28%
-28.18%
Return on equity
-1083.16%
-37.47%
Earnings Date
Last Earnings Date
Jan
1
Next Earnings Date
Jan
1
Estimated Next Earnings Date
Apr
2
Balance Sheet
KZIA
Sector
Total cash
$1.1M
$26.3M
Short term investments
--
$26M
Total assets
$4M
$76.9M
Long term debt
$423.8K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
